BCM
CCXI

Bluefin Capital Management’s ChemoCentryx, Inc. CCXI Stock Holding History

Bluefin Capital Management’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-35,614
Closed -$893K – 812
2022
Q1 		$893K Buy
+35,614
New +$1M 0.08% 141

Other funds holding CCXI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Bluefin Capital Management's CCXI Position: Q2 2022 in Review

Bluefin Capital Management sold out of ChemoCentryx, Inc. (CCXI) in Q2 2022, closing a stake of 35,614 shares — an estimated $893K sold.

Bluefin Capital Management first reported a position in CCXI in Q1 2022 and held it in 1 quarter. The position peaked at $893K in Q1 2022. 182 funds tracked by Wall St. Rank hold CCXI as of Q2 2022.

  • Bluefin Capital Management reported no remaining ChemoCentryx, Inc. position as of Q2 2022 after selling out during the quarter.
  • Bluefin Capital Management sold 35,614 ChemoCentryx, Inc. shares in Q2 2022, an estimated $893K.
  • Bluefin Capital Management first reported a position in ChemoCentryx, Inc. in Q1 2022 and held it in 1 quarter.
  • Bluefin Capital Management's ChemoCentryx, Inc. position peaked at $893K in Q1 2022.
  • 182 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q2 2022.

Based on Bluefin Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.